Originally posted on New Drug Approvals:
|Traded as||BSE: 532296NSE: GLENMARK)|
|Industry||Pharmaceuticals, Drugs &Healthcare|
|Headquarters||Mumbai, Maharashtra, India|
|Key people||Glenn Saldanha, MD & CEO |
|Products||Medicines and Vaccines|
|Revenue||1031.10 crore(US$160 million) (2009–2010)|
|Subsidiaries||Glenmark Generics Ltd|
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.  It manufactures and markets generic formulation products and active pharmaceutical ingredients (API), both in the domestic and international markets. In the formulation business, its business spans segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT andDiabetes.
It has four manufacturing facilities for formulations and additional three facilities for APIs. These manufacturing facilities are located in the states of Maharashtra, Goa, Himachal Pradesh and Gujarat in India.
View original 1,519 more words